Global Obstructive Lung Disease Management Markets 2021: Opportunities Led by Big Pharma and Medical Device Companies and New Collaborations in Developing Affordable and Quality-Driven Treatments
September 23, 2021 04:58 ET
|
Research and Markets
Dublin, Sept. 23, 2021 (GLOBE NEWSWIRE) -- The "Global Obstructive Lung Disease Management Market Report 2021" report has been added to ResearchAndMarkets.com's offering. The report provides a...
AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 16:30 ET
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...
AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)
August 18, 2021 07:05 ET
|
AzurRx BioPharma, Inc.
MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpointsStudy data indicates clinically meaningful improvement in coefficient of fat absorption (CFA) primary...
AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819
August 17, 2021 07:00 ET
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...
AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors
August 16, 2021 08:00 ET
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, therapies...
AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter’s Option to Purchase Additional Shares
July 27, 2021 16:30 ET
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., July 27, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock
July 22, 2021 16:51 ET
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
Prenatal and New-born Genetic Testing Market revenue to cross USD 9.5 Bn by 2027: Global Market Insights Inc.
July 07, 2021 05:00 ET
|
Global Market Insights, Inc
Selbyville, Delaware, July 07, 2021 (GLOBE NEWSWIRE) -- According to latest report “Prenatal and New-born Genetic Testing Market by Technology (Screening, Diagnostic), Disease (Downs Syndrome,...
Claire’s Place Foundation Partners with Woojer to Launch SICK BEATS
June 21, 2021 12:39 ET
|
Claire's Place Foundation
Los Angeles, CA, June 21, 2021 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is pleased to...
AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital
June 08, 2021 07:00 ET
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., June 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...